Babak Mesbahi, a presidium member of the Iranian Pharmacists Association, said sanctions are indirectly choking payment channels and logistics.
“Based on recent officials’ statements, the country’s medicine reserves on average are less than two months,” he said. “Infant formula faces a similar situation, and about 800 items will face shortages over the next three months.”
Mesbahi told Didban Iran that “Sanctions do not directly target medicine and infant formula, but their side effects are entirely palpable. Currency transfers have become difficult and allocation faces problems, and these issues are directly caused by sanctions.”
Asked whether the government has eased FX transfers, Mesbahi said: “As far as I know, nothing specific has been done. Right now there are pro forma invoices that have remained four to five months in the allocation and transfer queue,” he added.
The end of preferential exchange rates on many imported inputs has accelerated price rises for finished medicines and raw materials, according to pharmacists’ associations.
Hadi Ahmadi, a board member of the Iranian Pharmacists Association, said daily currency volatility and rising input costs are pushing up prices, even for common medicines.
“About 70% of production costs – packaging, auxiliaries and other inputs – follow the free-market exchange rate, and only roughly 30% relates to active ingredients, so price increases are unavoidable,” Ahmadi told ILNA.
“When prices rise and insurance does not keep pace, patients either take incomplete regimens or walk away, and the treatment path is disrupted.”
He added that only two to three million doses of influenza vaccine were imported versus a need of six to seven million for a population near 90 million, and distribution was late, which contributed to wider spread of flu.